

Table 6: Predicted Seroprevalence Rates for Each Alternative Using Deterministic (Averaging) Model

Alternative	Seroprevalence 2006 (assuming 70% efficacy)	Seroprevalence 2006 (assuming 25% efficacy)	Seroprevalence 2011 (assuming 70% efficacy)
1	33	40	24
2	34	45	26
3	36	45	28
4	34	42	26
5	0	0	0
6*	32	40	0
7	32	40	23
Modified Preferred	33	Not calculated	25

* For both vaccine efficacies, seroprevalence would be 0% after completion of capture, test, and slaughter operations by 2013.

[Previous Table](#)